NEW YORK (GenomeWeb) – German molecular diagnostics firm Epigenomics today reported a 6 percent drop in 2014 revenues due primarily to the phasing out of existing licensing agreements ahead of anticipated US commercialization of its Epi proColon blood-based test for the early detection of colorectal cancer.

In 2014, Epigenomics tallied €1.5 million ($1.6 million) in revenues compared to €1.6 million in 2013. Product sales increased to $800,000 in 2014 from $600,000 in 2013.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers test gene therapy targeting a different cancer protein in a new trial, the New York Times reports.

Pennsylvania State University researchers found that salivary microRNAs could predict which kids would have longer concussion symptoms, according to NPR.

The Associated Press reports Alex Azar, the new Department of Health and Human Services secretary nominee, made millions of dollars as a pharmaceutical executive.

In PNAS this week: immune profiling of breast cancer, transposable element patterns in rice, and more.